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Abstract
Background: Renal failure is a serious complication after cardiac surgery, which can be caused by long-term
intravenous (IV) loop diuretic use. Tolvaptan is an oral selective vasopressin-2 receptor antagonist used in patients
irresponsive to loop diuretics. We investigated their renal perfusion changes using the resistive index (RI) postoperatively.
Methods: Serial renal RI, echocardiography, and laboratory examinations from 14 patients requiring continuous
postoperative IV loop diuretics were reviewed. Eight patients received tolvaptan (Group T) and six received oral loop
diuretics before the discontinuation of IV loop diuretics (Group L). The 1st data were obtained between postoperative
day 0 and 2, the 2nd when patients were still under IV loop diuretic treatment, the 3rd after the initiation of tolvaptan or
oral loop diuretic, and the 4th after the discontinuation of IV diuretics.
Results: The 2nd RI value was higher in Group T than Group L (0.77 ± 0.09 vs. 0.69 ± 0.01, p = 0.049) but significantly
decreased after tolvaptan administration [0.77 ± 0.09 to 0.65 ± 0.05 (2nd to 3rd), to 0.62 ± 0.04 (to 4th), both p = 0.006],
while no such changes were seen in Group L. The serum sodium and albumin levels, and echo-derived tricuspid annular
plane systolic excursion increased only in Group T (134.1 ± 1.5 to 138.8 ± 3.2 mEq/L, 3.3 ± 0.3 to 3.7 ± 0.5 g/dL, 16.4 ± 3.6
to 19.7 ± 4.2 mm, all p <0.05). The duration of IV loop diuretics tended to be shorter in Group T than Group L (5.6 ± 1.6
vs. 8.7 ± 3.6 days, p = 0.051).
Conclusions: Administration of tolvaptan in patients undergoing cardiac surgery may improve their renal perfusion, as
reflected by the renal RI measured using renal Doppler ultrasound.
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Background
Renal functional deterioration provokes a serious com-
plication following cardiac surgery that is associated with
an increase in morbidity and mortality [1–3]. Although
the intravenous (IV) administration of loop diuretics is
frequently used during and immediately after cardiac
surgery, its high dose requirement is considered a risk
factor for worsening renal function as well as worsening
heart failure symptoms [4, 5]. The utilization of loop
diuretics decreases the glomerular filtration rate and
renal blood flow, which is closely linked to the activation of
renin-angiotensin-aldosterone systems (RAAS), resulting
in the deterioration of cardiac function, especially in
patients with heart failure [4–6]. In addition, prolonged
exposure to loop diuretics causes renal structural damages
to the kidneys, leading to diuretic resistance [4, 7].
Tolvaptan, an oral selective vasopressin two receptor
antagonist producing water diuresis, has been recently
used in patients with heart failure associated with vol-
ume overload refractory to conventional diuretic therapy
[8–10]. Since tolvaptan can remove excess water from
the body without activating the RAAS or causing serum
electrolyte imbalances, co-administration of tolvaptan
with loop diuretics is expected to reduce the required
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dose of loop diuretics and therefore ameliorate adverse
events and renal functional deterioration [11, 12].
Shirakabe et al. reported that the immediate adminis-
tration of tolvaptan in patients with acute decompensated
heart failure under the treatment of continuous IV loop
diuretics could reduce the amount of loop diuretics and
prevent the worsening of acute kidney injury [12].
However, the effect of tolvaptan on preventing
renal functional deterioration, especially on intra-
renal hemodynamics, by reducing the dose/duration
of IV diuretics in patients after cardiac surgery has
yet to be elucidated.
The renal resistive index (RI) in the intra-renal arteries
measured by Doppler ultrasound is a useful parameter
for quantifying the alterations in intrarenal perfusion
and renovascular resistance, which is an indicator for
the renal functional reserve [13–15]. The advantage of
using Doppler ultrasound over B-mode ultrasound in-
cludes its ability to detect not only renal morphological
abnormalities but also functional ones. B-mode ultra-
sound can evaluate kidney size, parenchymal thickness,
and changes in parenchymal echogenicity, but it is not
sensitive enough to diagnose acute renal injury [16]. On
the other hand, the measure RI has been reported to be
one of the most sensitive parameters detecting disease-
derived alterations of renal plasma flow [13–16]. The RI
was defined as a ratio of the difference between the
maximum and minimum flow velocity to maximum flow
velocity of intrarenal arteries [13–16]. A normal RI value
in subjects without pre-existing renal disease is reported
to be approximately 0.6 [17, 18], and a high RI is known
to be a maker of renal functional deterioration [14, 15].
In the present study, we investigated the serial changes
in RI and other renal functional parameters in patients
after cardiac surgery receiving tolvaptan while being
treated with IV loop diuretics, and the results were
compared with those conventionally treated with IV loop
diuretics followed by a conversion to oral loop diuretics.
Methods
Study design
This is a retrospective study at an institution with no
definite protocol for using tolvaptan as a part of the
renal sparing strategy after cardiac surgery. Still, serial
bedside echocardiography together with renal Doppler
ultrasound is routinely performed postoperatively, and
we aim to decrease the IV diuretic dosage if the patient’s
renal RI value is over 0.7. In such cases, oral tolvaptan
was initiated to maintain adequate urinary output while
the IV diuretic dosage was reduced, if their serum sodium
concentration was within a reasonable range and echocar-
diography did not indicate hypovolemic states (Fig. 1).
As a preliminary analysis, we reviewed data obtained
from 14 patients whose RI values were recorded at least
four times after cardiac surgery. Because we performed
renal Doppler ultrasound only in patients who required
continuous intravenous diuretics postoperatively, we were
unable to include their preoperative RI values in the
present investigation. Among the 14 patients we studied,
eight were treated with oral tolvaptan (Group T) and
six with oral loop diuretics (Group L) before the dis-
continuation of IV diuretics. Data including renal
Doppler ultrasonography were obtained from each pa-
tients at four time points. The 1st data were obtained
soon after surgery between postoperative day 0 and 2
(1st exam). The 2nd data were obtained after the 1st
exam while patients were still under continuous IV loop
diuretic treatment alone (2nd exam), and the subsequent
oral diuretic administration including the choice of drugs
was considered based on the 2nd exam results. The 3rd
data were obtained after the initiation of oral diuretics
(tolvaptan or oral loop diuretic) but with concomitant IV
loop diuretics (3rd exam). The 4th data were obtained
after the patients were successfully weaned from IV
loop diuretics and were treated with oral diuretics
alone (4th exam) (Fig. 1).
Ultrasonography
Standard echocardiography and renal ultrasound were
performed using the Vivid I digital ultrasound system
(GE Medical Systems, Horten, Norway). All measurements
obtained were in accordance with recommendations of the
American Society of Echocardiography [19, 20]. All echo
parameters were averaged for three consecutive beats. For
the RI measurements, patients were placed in a supine
position, and the flow velocities of intra-renal arteries at
the level of corticomedullary junction were measured using
pulsed Doppler ultrasonography. By using the highest
frequency probe, the sample volume was placed in the
lumen of the vessel and the speed–time curve was
recorded. The size of the sample volume must be set for
interlobar arteries (approximately 1–2 mm) in order to
avoid artifacts due to under or over sampling [16]. The RI
was calculated as; RI = (peak systolic velocity-end diastolic
velocity)/peak systolic velocity [13, 18].
Statistical analysis
Data are presented as mean ± SD. Normality was evalu-
ated for each variable from normal distribution plots and
histograms. Data were compared between the groups
using student’s unpaired two-tailed t-test for continuous
variables, and the chi-square test for categorical variables.
Repeated measures analysis of variance was used with
respect to the comparison of parameters for each group of
patients obtained at four time points. All data were
analyzed using the Statistical Analysis Systems software
JMP 11.0 (SAS Institute Inc. Cary, NC, USA).
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Results
Patients’ characteristics
The clinical characteristics of patients before and at the
time of cardiac surgery are summarized in Table 1. Age,
gender distribution, and body surface area were not
different between the groups. Preoperative laboratory
values including the estimated glomerular filtration rate
(eGFR) and echo-derived parameters were not signifi-
cantly different between the groups. The eGFR values in
both groups were around 50 mL/min/1.73 m2, and
one-third of patients in Group L and half in Group T suf-
fered from a chronic kidney disease stage >3b. Preopera-
tive general conditions including heart failure severity, as
reflected by NYHA class as well as the EuroScore and
Japan Score [21–23] tended to be worse in patients treated
with tolvaptan; however, the differences were not sta-
tistically different. Patients in Group T less frequently
underwent coronary bypass surgery alone than those
in Group L. This means patients treated with tolvap-
tan tended to have a disease affecting their right heart
function, although the number of patients in each
group was not statistically sufficient.
Serial changes in renal RI, echocardiographic and
laboratory values
Serial changes of ultrasound-derived parameters and la-
boratory values obtained from both groups are shown in
Table 2. In Group T, the 2nd RI values increased during
continuous IV loop diuretics from the 1st RI (p = 0.025);
however, the 3rd and 4th RI values decreased after tolvap-
tan administration (p = 0.006, p = 0.006, vs. 2nd value,
respectively) (Fig. 2). In contrast, the serial changes in RI
values were not significant in Group L. When we
compared the RI values at each time point between the
groups, the 2nd RI, which was the value measured during
continuous IV diuretic treatment before oral diuretic
administration, were higher in Group T than that in
Group L. However, after the initiation of oral diuretics
(tolvaptan for Group T, loop diuretics for Group L), the
RI values in Group L became rather higher than those in
Group T (Fig. 2).
The left ventricular end-diastolic dimension (LVEDD)
and left ventricular ejection fraction (LVEF) did not
change throughout the serial evaluation either in Group
T or Group L. In both groups, the maximum diameter
of the inferior vena cava (IVC) decreased at the 4th exam
compared to the initial and 2nd measurements (Fig. 3).
The LVEDD, LVEF, and IVC diameter at each time point
were not significantly different between the groups. The
tricuspid annular plane systolic excursion (TAPSE)
increased throughout the evaluation only in Group T
[Fig. 3]. The comparison of TAPSE between the groups
showed that the initial measurement of TAPSE tended
to be lower in Group T, and the 2nd measurement was
statistically lower in Group T than Group L.
Laboratory examination revealed that hemoglobin
concentrations tended to increase through the serial
measurements in both groups, but the changes were not
statistically significant. The serum sodium concentration
increased only in Group T. The sodium levels at 4th
measurements were higher than the 2nd measurements
in Group T, but such changes were not seen in Group L
(Fig. 3). The comparison of sodium concentrations at
each time point between the groups showed that the
values did not differ at 1st, 2nd, or 3rd measurements, but
it was higher in Group T than Group L at the 4th mea-
surements. Neither of the groups showed changes in
creatinine levels, and the values at each time point were
not significantly different between the groups. Both total
protein and albumin concentrations increased at the 4th
Fig. 1 A flow chart of treatment strategies in patients included in the study. WRF worsening of renal function, IV intravenous, echo echocardiography
and renal ultrasound
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measurements compared to the values at the 2nd mea-
surements in Group T, but such changes were not seen
in Group L (Fig. 3).
The duration of continuous IV diuretics treatment
tended to be shorter in Group T than Group L, but the
difference was not statistically significant.
Discussion
In this preliminary investigation, we focused on the
serial changes of renal RI values in patients requiring
continuous IV diuretics post-cardiac surgery, who were
treated with the co-administration of tolvaptan for early
discontinuation of IV diuretics and renal functional
preservation. Based on the fact that a high RI is reported
to be indicative of a decrease in renal perfusion which
would elicit renal functional deterioration [13–15, 17],
we considered starting tolvaptan but not oral loop di-
uretics in patients who showed RI elevations and/or
those with fluid overload associated with hyponatremia.
We have shown that, (i) the renal RI values decreased
in patients treated with tolvaptan administration, while
the values did not change in patients treated with oral
loop diuretics; (ii) not only serum sodium concentrations
but total protein and albumin levels also increased after
tolvaptan administration, suggesting that tolvaptan
effectively reduces “excessive” body fluid; (iii) tolvaptan
would be useful for shortening the duration of continuous
IV diuretics requirement after cardiac surgery, although
we failed to prove it statistically due to an insufficient
number of studied patients.
Renal dysfunction is a serious complication following
cardiac surgery, which has a strong impact on short- and
long-term morbidity and mortality [1–3]. Cardiopul-
monary bypass (CPB) usage during cardiac surgery is as-
sociated with an increased risk of acute renal dysfunction
[24, 25]. This is due to a decrease in renal blood flow
caused by hypotension under extracorporeal circulation
and low cardiac output immediately after weaning from
CPB, in addition to the inflammatory cytokines and ische-
mic reperfusion injury [3, 24, 25]. We recently reviewed
over 1500 patients undergoing cardiac surgery at our insti-
tution and found that CPB was a strong risk factor for the
postoperative requirement of renal replacement therapy
[26]. Therefore, we believe that keeping sufficient renal
perfusion after cardiac surgery is important in protecting
renal function, especially from the possible damage caused
by CPB. Indeed, all patients whom we treated with
tolvaptan in order to avoid further deterioration of renal
function caused by prolonged IV loop diuretics in the
present study underwent cardiac surgery using CPB.
The renal RI is defined as a ratio of the difference be-
tween the maximum and minimum (end-diastolic) flow
velocity to maximum flow velocity measured by renal
Doppler ultrasound [13, 18]. Because this is the ratio of
flow velocity, the results are independent from the types
of ultrasound machines. We routinely perform serial
bedside echocardiography postoperatively to evaluate
hemodynamics and to adjust the necessary medications;
therefore, adding renal Doppler ultrasounds to the routine
echo was simple and not at all time consuming. The RI is
a well-known indicator of renal perfusion, which is useful
for the prediction of renal function [13–15, 17, 27, 28]. In
the present observation, the RI values increased during
continuous IV diuretic infusion, which reflected the de-
terioration of renal perfusion, and normalized following
tolvaptan administration. In contrast, patients who were
treated with IV and oral loop diuretics did not show a
decrease in RI. This may indicate a possible renal sparing






Age (years) 61.5 ± 13.7 63.5 ± 11.5 0.7813
Men 5 (62.5 %) 3 (50.0 %) 0.1477
Body surface area (m2) 1.64 ± 0.11 1.60 ± 0.10 0.5998
NYHA class III or IV (n, %) 4 (50 %) 1 (16.7 %) 0.1977
Preoperative laboratory examinations
Hb (g/dL) 10.9 ± 1.8 10.4 ± 1.1 0.5397
Na (mEq/L) 139.1 ± 4.0 136.0 ± 3.6 0.1567
Cre (mg/dL) 1.20 ± 0.54 1.02 ± 0.28 0.478
T-Bil (mg/dL) 1.4 ± 0.6 1.02 ± 0.2 0.408
TP (g/dL) 6.2 ± 0.5 6.3 ± 0.2 0.792
Alb (g/dL) 3.5 ± 0.3 3.5 ± 0.2 0.831
eGFR (ml/min./1.73 m2) 47.6 ± 26.6 52.9 ± 14.4 0.668
CKD stage 3b or worse (n, %) 4 (50 %) 2 (33.3 %) 0.533
Preoperative echocardiography
LVEDD (mm) 56.8 ± 19.8 50.3 ± 9.4 0.371
LVEF (%) 43.1 ± 14.0 52.0 ± 6.7 0.180
TAPSE (mm) 16.0 ± 5.0 20.3 ± 3.1 0.086
RVFAC (%) 33.5 ± 7.1 38.3 ± 6.5 0.214
Euroscore 12.6 ± 8.1 8.0 ± 4.0 0.2486
Japan Score 15.9 ± 11.8 10.1 ± 5.1 0.2820
Type of surgery (p value based
on CABG alone vs. others)
0.0499
CABG alone 0 (0 %) 2 (33.3 %)
Valvular surgery alone 5 (62.5 %) 3 (50.0 %)
CABG + Valvular surgery 1 (12.5 %) 1 (16.7 %)
Pericardiectomy 1 (12.5 %) 0 (16.7 %)
Pulmonary thrombectomy 1 (12.5 %) 0 (16.7 %)
Abbreviations not defined in the text; NYHA New York Heart Association, Hb
hemoglobin, Na sodium; Cre creatinine, T-Bil total bilirubin, TP total protein, Alb
albumin, eGFR estimated glomerular filtration rate, CKD chronic kidney disease,
LVEDD left ventricular end-diastolic dimension, LVEF left ventricular ejection
fraction, TAPSE tricuspid annual plane systolic excursion, RVFAC right ventricular
fractional area change, CABG coronary artery bypass grafting
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Table 2 Serial changes in RI values and other examinations
Group T (n = 8) Group L (n = 6) p value intergroup comparison
1st exam 2nd exam 3rd exam 4th exam ANOVA p value 1st exam 2nd exam 3rd exam 4th exam ANOVA p value 1st exam 2nd exam 3rd exam 4th exam
Renal ultrasound
Renal RI 0.67 ± 0.05 0.77 ± 0.09 0.65 ± 0.05 0.62 ± 0.04 0.0002 0.66 ± 0.04 0.69 ± 0.01 0.71 ± 0.05 0.70 ± 0.04 0.2008 0.816 0.049 0.043 0.002
p value; vs. 1st exam – 0.025 0.425 0.093 – 0.203 0.096 0.196
p value; vs. 2nd exam – – 0.006 0.006 – – 0.341 0.485
Echocardiography
LVEDD (mm) 58.5 ± 19.8 55.1 ± 15.4 57.2 ± 16.5 56.1 ± 17.6 0.9823 50.3 ± 9.4 51.3 ± 10.3 51.0 ± 11.7 46.5 ± 6.7 0.8112 0.371 0.614 0.446 0.230
LVEF (%) 45.1 ± 15.2 44.9 ± 14.5 45.0 ± 14.0 47.0 ± 15.3 0.9902 53.3 ± 8.3 52.8 ± 9.5 55.8 ± 11.7 52.0 ± 0.3 0.9150 0.249 0.266 0.151 0.494
IVC diameter (mm) 23.1 ± 5.4 23.5 ± 3.2 21.5 ± 3.6 19.8 ± 3.2 0.2336 23.1 ± 5.4 21.5 ± 2.7 21.2 ± 3.2 18.2 ± 2.6 0.1475 0.379 0.240 0.860 0.439
p value; vs. 1st exam – 0.798 0.318 0.021 – 0.541 0.793 0.023
p value; vs. 2nd exam – – 0.049 0.004 – – 0.783 0.036
TAPSE (mm) 16.4 ± 3.6 17.5 ± 3.4 19.0 ± 4.1 19.7 ± 4.2 0.3165 19.8 ± 4.4 21.8 ± 2.8 21.5 ± 3.4 21.5 ± 3.8 0.7759 0.129 0.026 0.252 0.439
p value; vs. 1st exam – 0.380 0.041 0.015 – 0.216 0.387 0.419
p value; vs. 2nd exam – – 0.127 0.087 – – 0.771 0.813
Laboratory examinations
Hb (g/dL) 10.0 ± 1.4 9.7 ± 1.4 10.0 ± 1.1 10.5 ± 1.5 0.6340 9.3 ± 0.6 9.1 ± 0.7 9.9 ± 1.2 10.4 ± 1.1 0.0893 0.259 0.369 0.920 0.881
p value; vs. 1st exam – 0.456 0.977 0.323 – 0.567 0.267 0.130
p value; vs. 2nd exam – – 0.383 0.052 – – 0.283 0.110
Na (mEq/L) 136.3 ± 3.9 134.1 ± 1.5 136.4 ± 4.1 138.8 ± 3.2 0.0745 135.3 ± 2.2 135.0 ± 3.9 134.7 ± 2.3 134.7 ± 2.2 0.9699 0.616 0.571 0.384 0.019
p value; vs. 1st exam – 0.093 0.941 0.112 – 0.876 0.543 0.328
p value; vs. 2nd exam – – 0.170 0.005 – – 0.797 0.830
Cre (mg/dL) 1.1 ± 0.6 1.3 ± 0.7 1.2 ± 0.5 1.1 ± 0.4 0.8967 1.2 ± 0.5 1.2 ± 0.5 1.3 ± 0.3 1.3 ± 0.3 0.9180 0.841 0.914 0.584 0.271
p value; vs. 1st exam – 0.079 0.190 0.502 – 0.667 0.224 0.309
p value; vs. 2nd exam – – 0.388 0.189 – – 0.553 0.572
TP (g/dL) 6.0 ± 0.6 6.0 ± 0.5 6.0 ± 0.5 6.3 ± 0.4 0.9909 6.1 ± 0.4 6.0 ± 0.4 6.0 ± 0.5 6.1 ± 0.3 0.9763 0.923 0.880 0.987 0.308
p value; vs. 1st exam – 0.649 0.705 0.116 – 0.363 0.259 0.765
p value; vs. 2nd exam – – 0.756 0.042 – – 0.862 0.275
Alb (g/dL) 3.5 ± 0.4 3.3 ± 0.3 3.6 ± 0.2 3.7 ± 0.5 0.2227 3.4 ± 0.2 3.2 ± 0.3 3.4 ± 0.2 3.5 ± 0.1 0.0987 0.681 0.660 0.146 0.380
p value; vs. 1st exam – 0.174 0.329 0.351 – 0.056 0.998 0.555
p value; vs. 2nd exam – – 0.026 0.059 – – 0.071 0.073
Duration requiring IV loop
diuretics (days)
5.6 ± 1.6 8.7 ± 3.6 0.051
Abbreviations not defined in the text; LVEDD left ventricular end diastolic diameter, LVEF left ventricular ejection fraction, IVC inferior vena cava, TAPSE tricuspid annular plane systolic excursion, Hb hemoglobin,











effect of using tolvaptan to reduce the duration/dosage of
loop diuretics. We failed to show the difference between
serum creatinine levels of the two groups after discontinu-
ation of IV loop diuretics; however, we assume that
tolvaptan would be beneficial for maintaining the renal
functional reserve, as reflected by a decrease in the RI
observed in group T. Indeed, the volume overload status
was successfully corrected in both groups according to the
significant decrease in IVC diameter during the study
period in both groups. Even though we admit that the
number of cases was too small and the patients’ back-
grounds were not homogeneous between the groups,
tolvaptan treatment may have the potential to correct fluid
overload without affecting renal perfusion. This result
may be associated with the shortening of the duration as
well as the reduction of cumulative doses in IV loop
diuretic requirements [12]. Furthermore, the tolvaptan
administration successfully corrected hyponatremia
and hypoalbuminemia, both of which are known to
be associated with poor prognosis in heart failure pa-
tients [29, 30], although we have not yet investigated
the long-term effect of tolvaptan usage in this prelim-
inary analysis.
The timing of tolvaptan initiation is a difficult issue.
Loop diuretics are the most commonly-used diuretics to
treat volume overload, and are almost always administered
intravenously for patients in the intensive care unit
(ICU) including post-cardiac surgery. A multicenter,
multinational, observational study reported that about
70 % of patients in the ICU receive diuretics, with
furosemide being the choice of 98 % [31]. However,
the dose of loop diuretics leads to a decrease in renal
blood flow and is an independent negative predictor
of outcome in patients with heart failure [32]. Loop
diuretic-induced hyponatremia also provokes poor
prognosis [5, 33]. Unlike loop diuretics, tolvaptan does
not activate the renin-angiotensin-aldosterone (RAAS) sys-
tem and augments water excursion without changes in
renal hemodynamics. Therefore, tolvaptan usage combined
with reduced dosage of loop diuretics can be a reasonable
renal sparing strategy. Shirakabe et al. recently reported
that the immediate administration of tolvaptan can prevent
the progression of renal dysfunction and improve survival
in patients with acute decompensated heart failure [12]. In
their study, patients who received tolvaptan immediately
after admission together with intravenous loop diuretics
ended up requiring smaller amounts of furosemide than
those treated conventionally. The ACTIVE-HF trial
revealed that tolvaptan treatment reduce mortality when it
was initiated within 48 h [34], whereas the EVEREST trial
failed to show the survival benefit of tolvaptan treatment
when it was administrated more than 48 h after the
hospitalization [35]. This may indicate that the benefi-
cial effect of tolvaptan on renal functional preservation
as well as the prognosis is more expected when it is
administrated in the early phase of fluid management,
rather than when it is used after sufficient conventional
diuretic therapy. Therefore, we may be able to suggest that
tolvaptan treatment, as a renal sparing strategy, should be
initiated without waiting for the development of signs
of worsening renal failure such as a slight increase in
creatinine levels. In other words, creatinine-guided or
diuretic dosage-guided tolvaptan initiation may not be
always appropriate. In our study, we utilized renal
Doppler ultrasound-derived RI values as a guide to decide
the timing of tolvaptan initiation. The RI values can be
used to discriminate functional/reversible acute kidney
injury (AKI) from organic/persistent AKI. The functional
Fig. 2 Serial changes in renal RI values in both groups. Black dots and bars indicate the mean ± SD of RI values in patients receiving tolvaptan
(Group T). Red dots and bars indicate the mean ± SD of RI values in patients receiving oral loop diuretics (Group L)
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AKI is characterized by a reduction in renal perfusion and
is rapidly reversible if promptly treated [16]. Indeed, as we
applied RI values in the present study, previous studies
also reported that RI is a good predictor of the onset of
AKI in the early postoperative period of patients undergo-
ing cardiac surgery [36, 37] Considering the high sensitiv-
ity and specificity (both >80 %) of the RI as an indicator
for persistent AKI [16, 38], as well as the fact that it does
not require blood or urine samples and can be performed
at the bedside, it could be used to determine the optimal
timing of initiating tolvaptan to reduce loop diuretics.
The present study had several limitations. First, this is a
single-center, retrospective observational analysis based
on a small number of patients. Because this is a prelimin-
ary report to investigate the utility of serial RI measure-
ments, we failed to include preoperative RI measurements
in the present cohort. However, considering the fact that
the RI is a useful parameter to predict not only the
worsening but also the recovery of renal function by
reflecting the renal functional reserve [13–15], we are now
planning to include renal Doppler ultrasound as a part of
the preoperative evaluation in patients undergoing cardiac
surgery at our institution in a routine manner. In addition,
operative profiles were not homogeneous among the
groups. However, we believe that our present report may
reflect the discretion in the real clinical world about
diuretic usage and the attempt of sparing renal function.
We cannot emphasize that patients receiving tolvaptan in
the present study tended to have fluid accumulation asso-
ciated with right-sided heart failure; however, we assume
that tolvaptan may be a potent therapy in patients with an
upregulation of vasopressin derived from persistent renal
congestion. Second, the exact timing of obtaining the data
was different between the groups, although the conditions
Fig. 3 Serial changes in ultrasound and laboratory parameters obtained from patients receiving tolvaptan (upper) and those obtained from patients
receiving oral loop diuretics (lower). Black dots and lines indicate the RI values, gray dots and lines indicate IVC diameters, purple dots and lines indicate
TAPSE, blue dots and lines indicate serum sodium concentrations, green dots and lines indicate serum albumin levels, and orange dots and lines indicate
serum creatinine levels. Na sodium, Alb albumin, Crea creatinine
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of patients under either of the targeted drug usages were
consistent. Third, we did not include information on drug
usages other than diuretics such as inotropic agents and
beta-blockers. Finally, we reviewed only the short-
term clinical course and did not review long-term
outcomes.
Conclusions
In conclusion, the administration of tolvaptan after
cardiac surgery in patients who require continuous IV
diuretics may improve their renal perfusion, as reflected
by the renal RI measured using renal Doppler ultrasound.
Abbreviations
CPB: cardiopulmonary bypass; eGFR: estimated glomerular filtration rate;
ICU: intensive care unit; IV: intravenous; IVC: inferior vena cava; LVEDD: end-
diastolic dimension; LVEF: left ventricular ejection fraction; RI: resistive index;
TAPSE: tricuspid annular plane systolic excursion.
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